HH-30134 / HaiHe Biopharma - LARVOL DELTA

First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=22 | Terminated | Sponsor: Haihe Biopharma Co., Ltd. | N=50 ➔ 22 | Trial completion date: Jun 2023 ➔ Mar 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2023 ➔ Mar 2023; Sponsor business decision

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2022 ➔ Jun 2023

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Haihe Biopharma Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Oncology • Solid Tumor

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH30134 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: ShangHai HaiHe Pharmaceutical

Clinical • New P1 trial • Oncology • Solid Tumor